Biotech

All Articles

Angelini pens $360M biobucks pact for ph. 1 brain ailment medicine

.Italy's Angelini Pharma has signed a $360 million biobucks deal centered on a stage 1-stage brain h...

Sage gives up half of R&ampD staff and agitates C-suite again

.Sage Therapeutics' most up-to-date attempt to reduce its own pipeline and workforce will see a thir...

With period 1 data, Feeling possesses an eye on early-stage sac cancer cells

.Along with its lead candidate in a phase 3 trial for an uncommon eye cancer, Aura Biosciences is se...

Less than a year in, BenevolentAI CEO is out-- Chutes &amp Ladders

.Welcome to this week's Chutes &amp Ladders, our summary of considerable leadership hirings, firings...

Roche MAGE-A4 trial taken out after key review

.Roche has produced yet another MAGE-A4 program go away, withdrawing a period 1 trial of a T-cell bi...

FDA puts partial hang on BioNTech-OncoC4 phase 3 trial

.The FDA has actually implemented a predisposed hold on a period 3 non-small mobile lung cancer cell...

REGiMMUNE, Kiji combine to produce Treg 'incredibly provider,' plan IPO

.Taiwan's REGiMMUNE and also Europe-based Kiji Rehabs are actually combining to create an around the...

With trial gain, Merck aims to take on Sanofi, AZ in RSV

.3 months after disclosing that its own respiratory syncytial virus (RSV) precautionary antibody cle...

Noema checks off period 2a Tourette succeed for ex-Roche molecule

.Noema Pharma has acquired a phase 2a gain for its Tourette disorder medicine candidate, reporting a...

Terray assembles $120M collection B to advance AI-powered molecules

.Terray Therapies has brought in $120 thousand for a set B fundraise as the AI-focused biotech aims ...